Citi Pharma Limited has formally submitted a non-binding offer for the potential acquisition of a prominent pharmaceutical company in Pakistan, as disclosed in a notification to the Pakistan Stock Exchange (PSX) on April 16, 2025.
Read More: WHO and Pakistan call for urgent investment to end tuberculosis
This move signals a significant step in Citi Pharma’s broader strategic expansion plan, aimed at solidifying its position as a leading player in Pakistan’s pharmaceutical landscape.
In its official communication to PSX, the company stated, “The submission of the non-binding offer is part of our ongoing strategic expansion plans of the Company to become one of the largest players in the pharma industry of Pakistan.”
While the identity of the target company and financial terms remain undisclosed, Citi Pharma noted that the next steps will depend on the completion of a comprehensive due diligence process. The transaction will also be subject to approval by the company’s Board of Directors and other relevant regulatory bodies.
This potential acquisition, if finalized, would mark a major milestone in Citi Pharma’s growth journey and could significantly enhance its production capabilities, market share, and contribution to the healthcare ecosystem in Pakistan.
